Company intelligence / Profile preview
DreamTec
Kwai Chung, Kowloon, Hong Kongdreamtecsystems.com ↗
- Ownership
- Public · A192650
- Development stage
- Other
01
Overview
DreamTec has developed a novel oral COVID‑19 vaccine using genetically engineered Bacillus subtilis spores displaying the SARS-CoV‑2 spike protein receptor-binding domain. Pilot studies in healthy volunteers showed increased neutralizing antibody levels after administration. Preclinical animal data indicated no alarming side effects and induction of IgG/IgM antibodies. The product aims to be stable at room temperature for up to six months and easy to administer orally; Phase I trials are planned or imminent as of the latest reports.
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- Recombinant proteinRNA therapyStem cell therapyExosome-based therapyMicrobial therapy3D bioprinting
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Chinese University of Hong KongHong Kong Metropolitan University
04
Financials
- Market cap
- $29.3B
- Total revenue
- $6.5B
- Enterprise value
- $45.1B
Beyond the preview
Go deeper on DreamTec.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DreamTec.